Peritonitis: Spectrum of bacteria and the role of antibiotics

Digestive Surgery

Volumn 13, Issue 4-5, 1996, Pages 390-395

  Malinverni, Raffaele ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bacterial pathogenesis; Peritonitis; Treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; CEFOXITIN; CEPHALOSPORIN; CEPHAMYCIN; CLINDAMYCIN; GENTAMICIN; IMIPENEM; LATAMOXEF; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIMICROBIAL THERAPY; BACTEROIDES FRAGILIS; CANDIDA; ENTEROCOCCUS; ESCHERICHIA COLI; HUMAN; PERITONITIS; REVIEW; TREATMENT FAILURE;

EID: 0029815007     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000172470     Document Type: Article

References (55)

1. Hau T, Ahrenholz DH, Simmons RL: Secondary bacterial peritonitis: The biologic basis of treatment, Curr Prob Surg 1979:16:1-65.
2. Dunn DL, Barke RA, Ahrenholz DH, Humphrey EW, Simmons RE: The adjuvant effect of peritoneal fluid in experimental peritonitis: Mechanism and clinical implication, Ann Surg 1984;199:37-43.
3. Lee JT Jr., Ahrenholz DH, Nelson RD, Simmons RL: Mechanisms of the adjuvant effect of hemoglobin in experimental peritonitis, V: The significance of the coordinated iron component, Surgery 1979:86:41-48.
4. Dunn DL, Simmons RL: The role of anaerobic bacteria in intraabdominal infections, Rev Infect Dis 1984;6(suppl 1): 139-146.
5. Poenaru D, De Santis M, Christou NV: Imi-penem versus tobramycin-ant¡anaerobe antibiotic therapy in intra-abdominal infections, Can J Surg 1990:33:415-422.
6. Slone HH, Kolb LD, Gcheber CE: Incidence and significance of intraperitoncal anaerobic bacteria, Ann Surg 1975;181:705-715.
7. Ruddell WSJ, Axon ATR, Findlay JM: Effect of cimetidinc on the gastric bacterial flora, Lancet 1980;1:672-674.
8. Simon GL, Gorbach SL: Intestinal flora in health and disease, Gastroenterology' 1984:86: 174-193.
9. Brook I:A12-year study of aerobic and anaerobic bacteria in intraabdominal and postsurgical wound infections, Surg Gynecol Obstet 1989; 169:387-392.
10. Gonzenbach HR, Simmcn HP, Amgwcrd R: Imipcnem versus netilmicin plus clindamycin, Ann Surg 1986;205:271-275.
11. Hackford AW, Tally FP, Rein hold RB, Barza M, Gorbach SL: Prospective study comparing imipcnem cilastatin with clindamycin and gen-tamicin for the treatment of serious surgical infections, Arch Surg 1988;123:322-326.
12. Walker AP, Nichols RL, Wilson RF: Efficacy of a betalactamasc inhibitor combination for serious intraabdominal infections, Ann Surg 1993:217:115-121.
13. Solomkin JS, Dellinger EP, Christou NV, Bu-suttil RW: Results of a multiccnter trial comparing imipcncm/cilastatin to tobramycin/clindamycin for intraabdominal infections, Ann Surg 1990;212:581-591.
14. Mosdell DM, Morris DM, Vollura A, Pitcher DE, Twiest MW, Milne RL, Miscall BG, Fry DE: Antibiotic treatment for surgical peritonitis, Ann Surg 1991:214:543-552.
15. Sawyer RG, Rosenlof LK, Adams RB, May AK, Spengler MD, Pruett TL: Peritonitis into the 1990s: Changing pathogens and changing strategies in the critically ill, Am Surg 1992:58: 82-87.
16. Rotstcin OD, Pruett TL, Sommins RL: Microbiologic features and treatment of persistent peritonitis in patients in the intensive care unit, Can J Surg 1986:29:247-250.
17. McClean KL, Sheehan GJ, KardingGKM: Intraabdominal infection: A review, Clin Infect Dis 1994;19:100-116.
18. Bartlett JG, Ondcrdonk AB, Louie T, Kasper DL, Gorbach SL: Lessons from an animal model of intraabdominal sepsis, Arch Surg 1978; 113:853-857.
19. Weinstein WM, Onderdonk AB, Bartlett JG: Experimental intraabdominal abscesses in rats: Development of an experimental model, Infect Immun 1974:10:1250-1255.
20. Onderdonk AB, Bartlett JG, Louie TJ, Sullivan Scigler N, Gorbach SL: Microbial synergy in experimental intraabdominal abscess, Infect Immun 1976:13:22-26.
21. Wilson SE, Hopkins JA: Clinical correlates of anaerobic bacteriology in peritonitis, Clin Infect Dis 1995;20(suppl 2):251-256.
22. Weinstein WM, Ondcrdonk AB, Bartlett JG, Louie TJ, Gorbach SL: Antimicrobial therapy of experimental intraabdominal sepsis, J Infect Dis 1975:132:282-286.
23. Baric PS, Christou NV, Dellinger EP, Rout WR, Stone HH, Wavmack JP: Pathogenicity of the enterococcus in surgical infections, Ann Surg 1990;212:155-159.
24. Maki DG, Agger WA: Enlcrococcal bacteremia: Clinical features, the risk of endocarditis, and management, Medicine 1988:67:248-269.
25. Bohncn JMA, Solomkin DS, Dellinger EP, Bjornson HS, Page CP: Guidelines for clinical care: Anti-infective agents for intraabdominal infection, Arch Surg 1992:127:83-89.
26. Morris JG, Shay DK, Hebden JN, McCarter RJ, Perdue BE, Jarvis W, Johnson JA, Dowling TC, Polish LB, Schwalbe RS: Enterococci resistant to multiple agents, including vancomycin, Ann Intern Med 1995;123:250-259.
27. Centers for Disease Control and Prevention: Preventing the spread of vancomycin resistance, Infect Control Hosp Epidemiol 1995:16: 105-113.
28. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P: Clinical significance ofCandidaisolated from peritoneum in surgical patients, Lancet 1989;2: 1437-1440.
29. Rutledge R, Mandel SR, Wild RE:Candidaspecies: Insignificant contaminant or pathogenic species, Am Surg 1983;198:42-47.
30. Gaines JD, Remington JS: Disseminated candidiasis in the surgical patient, Surgery 1972: 72:730-736.
31. Bayer AS, Btumenkrantz MJ, Montgomerie JZ, Galpin JE, Cobum JW, Guzc LB:Candidaperitonitis: Report of 22 cases and review of the English literature, Am J Med 1976;61:832-840.
32. Marsh PK, Tally FP, Kellum J, Callow A, Gorbach SL:Candidainfections in surgical patients, Ann Surg 1983;198:42-47.
33. Solomkin JS, Flohr A, Simmons RL:Candidainfections in surgical patients: Dose requirements and toxicity of amphotericin B, Ann Surg 1982;95:177-185.
34. Dougherty SH, Saltzstcin EC, Peacock JB, Mercer LC, Cano P: Perforated or gangrenous appendicitis treated with aminoglycosides: How do bacterial cultures influence management: Arch Surg 1989:124:1280-1283.
35. McNamara MJ, Pasquale MD, Evans SRI: Acute appendicitis and the use of intraperito-ncal cultures, Surg Gynecol Obstet 1993:177: 393-397.
36. Hopkins JA, Lee JCH, Wilson SE: Susceptibility of intra-abdominal isolates at operation: A predictor of postoperative infection, Am Surg 1993;59:791-796.
37. Thadcpalli H, Gorbach SL, Broido PW, Nor-sen J, Nvhus L: Abdominal trauma, anaerobes, and antibiotics, Surg Gynecol Obstet 1973:137: 270-276.
38. Berne TV, Yellin AE, Applcman MD, Hesel-tine PNR: Antibiotic management of surgically treated gangrenous or perforated appendicitis: Comparison of gentamicin and clindamycin versus ccfamandole versus cefoperazone, Am J Surg 1982:144:8-13.
39. Heseltinc PNR, Yellin AE, Applcman MD, Gill MA, Chcnella FC, Kern JW, Berne TV: Perforated and gangrenous appendicitis: An analysis of antibiotic failure, J Infect Dis 1983: 148:322-329.
40. Wilson SE, Boswick JA, Duma RJ, Echols RM, Jensek JG, Lerner R, Lewis RT, Najen AZ, Press RA, Rittenbury MS: Cephalosporin therapy in intraabdominal infections: A multicenter randomized, comparative study of cefotc-tan, moxalactam and cefoxitin, Am J Surg 1988:155:61-66.
41. Bennion RS, Thompson JE, Baron EJ, Fine-gold SM: Gangrenous and perforated appendicitis with peritonitis: Treatment and bacteriology, Clin Ther 1990: 12(suppl C):31-44.
42. Gribble MJ, Chow AW, Naiman SC, Smith JA, Bowie WR, Sacks SL, Grossmann L, Buskard N, Growe GIL Plcndcrlcith LH: Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serous bacterial infections, Antimicrob Agents Chemother 1983:24:388-393.
43. Ho JL, Barza M: Role of aminoglycosides in the treatment of intraadominal infection, An-limicrob Agents Chemother 1987:31:485-491.
44. Parker SE, Davey PG: Oncc-daily aminogveo-sidc dosing, Lancet 1993:341:346-347.
45. Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, Schaad U, Hcrtcr C, Eggimann P, Huber O, Ricou O, Suter P, Auck-enthaler R, C'hiolero R, Bille J, Schcidegger C, Frei R, Glauscr MP: Prospective randomized comparison of imipcnem monotherapy with imipcnem plus netilmicin for treatment of severe infections in nonneutropcnic patients, Antimicrob Agents Chemother 1994:38:1309-1313.
46. Schentag JJ, Weis PB, Reiberg DP, Walczak P, Hawkins van Tvle J, Lascola R: A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis, Ann Surg 1983:198:35-41.
47. Nichols RL, Smith JW, Klein DB: Risks of infection after penetrating abdominal trauma, N Engl J Med 1984; 311:1066-1070.
48. Solomkin JS, Kant WK, Rivera JO, Alexander JW: Randomized trial of imipencm/cilastatin versus gentamicin and clindamycin in mixed llora infections, Am J Med 1985:78(suppl 6A): 85-91.
49. Polk HC, Fink MP, Lavcrdiere M, Wilson SE, Garber GE, Barie PS, Hebert JC, Cheadle WG: Prospective randomized study of piperacillin/ tazobactam therapy of surgically treated intraabdominal infection, Am Surg 1993.59: 598-605.
50. Tally FP, Kellum JM, Ho JL, O’Donnell TF, Barza M, Gorbach SL: Randomized prospective study comparing moxalactam and cefoxitin with or without tobramycin for the treatment of serious surgical infections, Antimicrob Agents Chemother 1986;29:244-249.
51. Williams RR, Hotchkin D: Aztreonam plus clindamycin versus tobramycin plus clindamycin in the treatment of intraabdominal infections, Rev Infect Dis 1991;13(suppl 7):629-633.
52. Dellinger EP: Intraabdominal infection: Monotherapy versus combination therapy; in Sande M, Root RK (eds): Contemporary Issues in Infectious Diseases, New York, Churchill Livingstone, 1992. voi 9. pp 15-26.
53. Wilson SE, Nord CE: Clinical trials of extended spectrum penicillin/betalactamasc inhibitors in the treatment of intra-abdominal infections: European and North American experience, Am J Surg 1995.169 (suppl 5A):21-26.
54. Brismar B, Malmborg AS, Tuncvall G, Wrct-lind B, Bergman L: Piperacillin/tazobactam versus ini ipenem/cilastal in for t rcat mcnt of in-traabdominal infections, Antimicrob Agents Chemother 1992:36:2766-2773.
55. Niinikoski J, Havia T, Alhava E, Pääkkonen M, Miettinen P: Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intraabdominal infections, Surg Gynecol Obstet 1993;176:255-261.